CIVIC: University of Georgia Center for Influenza Vaccine Research in High Risk Populations

CIVIC：乔治亚大学高危人群流感疫苗研究中心

基本信息

批准号：
10621131
负责人：
TED ROSS
金额：
$ 1018.84万
依托单位：
UNIVERSITY OF GEORGIA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-10 至 2023-05-14
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10621131
关键词：
Adjuvant Animal Model Animals Area Bioinformatics Biological Assay Biometry Categories Contractor Contracts Couples Development Effectiveness Elderly Environment Evaluation Genetic Human Human Volunteers Immune Immune response Immunity Immunologics Immunology Individual Infection Modeling Mucous Membrane National Institute of Allergy and Infectious Disease Pathologic Persons Phase I/II Clinical Trial Population Reagent Recording of previous events Research Research Design Research Personnel Resources Saint Jude Children&apos s Research Hospital Statistical Models Systems Biology United States National Institutes of Health Universities Vaccinated Vaccination Vaccine Design Vaccine Research Vaccines Vulnerable Populations Work anti-influenza base early phase clinical trial healthy volunteer high risk high risk population immunogenicity influenza virus vaccine innovation next generation novel novel vaccines obese person pre-clinical pregnant programs response seasonal influenza skills standard of care structural biology universal influenza vaccine universal vaccine vaccine candidate vaccine development vaccine response vaccine strategy virology

项目摘要

The objective of this contract program is to support improvements in the immunogenicity and durability of seasonal influenza vaccines, and the development of innovative influenza vaccine approaches that provide robust, durable, broadly protective mucosal and systemic anti-influenza immunity (“universal influenza vaccines”). This will be done through NIAID-supported Collaborative Influenza Vaccine Innovation Centers (CIVICs). Each CIVIC will support iterative vaccine design based on detailed immunologic assessment of influenza vaccine candidates through pre-clinical animal studies, early phase clinical trials and healthy volunteer human challenge studies to advance the most promising vaccine candidates into Phase I/II clinical trials. University of Georgia’s Center for Influenza Vaccine Research in High Risk Populations (CIVR-HRP) builds upon many years of collaborative work by the primary investigators, and proposes a comprehensive research program centering on identifying broadly protective influenza vaccines for all populations with a focus on our most vulnerable populations. The program couples the skills of established and junior investigators, and combines our historical program strengths in vaccine development, virology, immunology, animal models, validated assay and reagent development, systems biology, bioinformatics and structural biology, and their extensive and world-class facilities and resources including St Jude Children’s Research Hospital (SJCRH) GMP facility with novel and innovative study designs such as comprehensive assessment of immune and omics responses to vaccination, novel platforms and adjuvants, and exploration of immune correlates of protective immunity in high-risk populations.

该合同计划的目的是支持季节性影响疫苗的免疫原性和耐用性的改善，以及创新影响疫苗方法的发展，这些方法提供了可靠，耐用，广泛保护的粘膜和全身性抗炎性免疫（“普遍影响疫苗”）。这将通过NIAID支持的合作流感疫苗创新中心（CIVICS）来完成。每个公民将通过临床前动物研究，早期临床试验和健康的志愿人类挑战研究来支持候选疫苗候选疫苗的详细免疫学评估的迭代疫苗设计，以将最有前途的候选疫苗候选者推向I/II期临床试验。佐治亚大学高风险人群中的流感疫苗研究中心（CIVR-HRP）建立在主要研究人员多年的协作工作的基础上，并提出了一项全面的研究计划，旨在确定所有人群的广泛保护影响疫苗，侧重于我们最脆弱的人群。该计划融合了已建立和初级研究人员的技能，并结合了我们在疫苗开发，病毒学，免疫学，动物模型，经过验证的评估和试剂开发，系统生物学，生物信息学和结构生物学以及其广泛和世界范围内的设施和资源（包括St. Jude儿童研究医院（SJCRH）的广泛的设施和资源的广泛的设施（SJCRH），包括Immut and Ingul om gmp gmp gmp gmp themogy and Insovials（SJCRH），将我们的历史计划优势结合在一起对疫苗接种，新型平台和调节器的反应，以及对高风险人群保护性免疫相关的免疫学相关性。